mpc controller block Search Results


clone mpc 11 mouse mouse igg2b κ  (Revvity)
91
Revvity clone mpc 11 mouse mouse igg2b κ
a) PD-1 binding capacity of <t>IgG1-FC</t> (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC was measured using a functional ELISA, where mean OD was measured at varying concentrations of IgG1-FC, rhPD-L1-FC or sec-PD-L1-long-FC protein. Kd values are displayed. The corresponding Scatchard graph displaying the differences in slope (−1/Kd) of rhPD-L1-FC (medium gray) or sec-PD-L1-long-FC (light gray) is shown as an inset. Data is from two separate experiments. b) The ability of PD-L1 and PD-1 neutralizing antibodies (10ug/ml) to block PD-1 binding to rhPD-L1-FC and sec-PD-L1-long-FC was tested with a functional ELISA. An IgG1 isotype control antibody was used as a negative control. Normalized mean OD values compared to incubation with the appropriate IgG1 isotype control conditions are plotted. Data is from two separate experiments. A two-way ANOVA was used. The mean and SEM are plotted. c, d) Primary human T cell blasts were incubated with IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC at either 20ug/ml or 40ug/ml in the presence of anti-CD3 for 24 hours, and media was harvested to quantify c) IL-2 and d) IFNg with ELISA. Samples were run in duplicate. N=5. Normalized protein levels compared to the appropriate IgG1-Fc control are plotted. A one-way ANOVA was used. The mean and SEM are plotted. *p<0.05, **p<0.01, ***p<0.001
Clone Mpc 11 Mouse Mouse Igg2b κ, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clone mpc 11 mouse mouse igg2b κ/product/Revvity
Average 91 stars, based on 1 article reviews
clone mpc 11 mouse mouse igg2b κ - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
mouse igg2b mpc 11  (Bio X Cell)
94
Bio X Cell mouse igg2b mpc 11
a) PD-1 binding capacity of <t>IgG1-FC</t> (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC was measured using a functional ELISA, where mean OD was measured at varying concentrations of IgG1-FC, rhPD-L1-FC or sec-PD-L1-long-FC protein. Kd values are displayed. The corresponding Scatchard graph displaying the differences in slope (−1/Kd) of rhPD-L1-FC (medium gray) or sec-PD-L1-long-FC (light gray) is shown as an inset. Data is from two separate experiments. b) The ability of PD-L1 and PD-1 neutralizing antibodies (10ug/ml) to block PD-1 binding to rhPD-L1-FC and sec-PD-L1-long-FC was tested with a functional ELISA. An IgG1 isotype control antibody was used as a negative control. Normalized mean OD values compared to incubation with the appropriate IgG1 isotype control conditions are plotted. Data is from two separate experiments. A two-way ANOVA was used. The mean and SEM are plotted. c, d) Primary human T cell blasts were incubated with IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC at either 20ug/ml or 40ug/ml in the presence of anti-CD3 for 24 hours, and media was harvested to quantify c) IL-2 and d) IFNg with ELISA. Samples were run in duplicate. N=5. Normalized protein levels compared to the appropriate IgG1-Fc control are plotted. A one-way ANOVA was used. The mean and SEM are plotted. *p<0.05, **p<0.01, ***p<0.001
Mouse Igg2b Mpc 11, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg2b mpc 11/product/Bio X Cell
Average 94 stars, based on 1 article reviews
mouse igg2b mpc 11 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
nonlinear mpc controller block  (MathWorks Inc)
95
MathWorks Inc nonlinear mpc controller block
a) PD-1 binding capacity of <t>IgG1-FC</t> (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC was measured using a functional ELISA, where mean OD was measured at varying concentrations of IgG1-FC, rhPD-L1-FC or sec-PD-L1-long-FC protein. Kd values are displayed. The corresponding Scatchard graph displaying the differences in slope (−1/Kd) of rhPD-L1-FC (medium gray) or sec-PD-L1-long-FC (light gray) is shown as an inset. Data is from two separate experiments. b) The ability of PD-L1 and PD-1 neutralizing antibodies (10ug/ml) to block PD-1 binding to rhPD-L1-FC and sec-PD-L1-long-FC was tested with a functional ELISA. An IgG1 isotype control antibody was used as a negative control. Normalized mean OD values compared to incubation with the appropriate IgG1 isotype control conditions are plotted. Data is from two separate experiments. A two-way ANOVA was used. The mean and SEM are plotted. c, d) Primary human T cell blasts were incubated with IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC at either 20ug/ml or 40ug/ml in the presence of anti-CD3 for 24 hours, and media was harvested to quantify c) IL-2 and d) IFNg with ELISA. Samples were run in duplicate. N=5. Normalized protein levels compared to the appropriate IgG1-Fc control are plotted. A one-way ANOVA was used. The mean and SEM are plotted. *p<0.05, **p<0.01, ***p<0.001
Nonlinear Mpc Controller Block, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlinear mpc controller block/product/MathWorks Inc
Average 95 stars, based on 1 article reviews
nonlinear mpc controller block - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
mouse igg2b isotype control  (Bio X Cell)
94
Bio X Cell mouse igg2b isotype control
(A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype <t>IgG</t> and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.
Mouse Igg2b Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg2b isotype control/product/Bio X Cell
Average 94 stars, based on 1 article reviews
mouse igg2b isotype control - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

Image Search Results


a) PD-1 binding capacity of IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC was measured using a functional ELISA, where mean OD was measured at varying concentrations of IgG1-FC, rhPD-L1-FC or sec-PD-L1-long-FC protein. Kd values are displayed. The corresponding Scatchard graph displaying the differences in slope (−1/Kd) of rhPD-L1-FC (medium gray) or sec-PD-L1-long-FC (light gray) is shown as an inset. Data is from two separate experiments. b) The ability of PD-L1 and PD-1 neutralizing antibodies (10ug/ml) to block PD-1 binding to rhPD-L1-FC and sec-PD-L1-long-FC was tested with a functional ELISA. An IgG1 isotype control antibody was used as a negative control. Normalized mean OD values compared to incubation with the appropriate IgG1 isotype control conditions are plotted. Data is from two separate experiments. A two-way ANOVA was used. The mean and SEM are plotted. c, d) Primary human T cell blasts were incubated with IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC at either 20ug/ml or 40ug/ml in the presence of anti-CD3 for 24 hours, and media was harvested to quantify c) IL-2 and d) IFNg with ELISA. Samples were run in duplicate. N=5. Normalized protein levels compared to the appropriate IgG1-Fc control are plotted. A one-way ANOVA was used. The mean and SEM are plotted. *p<0.05, **p<0.01, ***p<0.001

Journal: Cancer immunology, immunotherapy : CII

Article Title: Identification and characterization of an alternative cancer-derived PD-L1 splice variant

doi: 10.1007/s00262-018-2284-z

Figure Lengend Snippet: a) PD-1 binding capacity of IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC was measured using a functional ELISA, where mean OD was measured at varying concentrations of IgG1-FC, rhPD-L1-FC or sec-PD-L1-long-FC protein. Kd values are displayed. The corresponding Scatchard graph displaying the differences in slope (−1/Kd) of rhPD-L1-FC (medium gray) or sec-PD-L1-long-FC (light gray) is shown as an inset. Data is from two separate experiments. b) The ability of PD-L1 and PD-1 neutralizing antibodies (10ug/ml) to block PD-1 binding to rhPD-L1-FC and sec-PD-L1-long-FC was tested with a functional ELISA. An IgG1 isotype control antibody was used as a negative control. Normalized mean OD values compared to incubation with the appropriate IgG1 isotype control conditions are plotted. Data is from two separate experiments. A two-way ANOVA was used. The mean and SEM are plotted. c, d) Primary human T cell blasts were incubated with IgG1-FC (negative control), rhPD-L1-FC (positive control) or sec-PD-L1-long-FC at either 20ug/ml or 40ug/ml in the presence of anti-CD3 for 24 hours, and media was harvested to quantify c) IL-2 and d) IFNg with ELISA. Samples were run in duplicate. N=5. Normalized protein levels compared to the appropriate IgG1-Fc control are plotted. A one-way ANOVA was used. The mean and SEM are plotted. *p<0.05, **p<0.01, ***p<0.001

Article Snippet: For PD-L1 surface staining of cancer cell lines, cells were stained as described with the following antibodies: anti-human CD274-APC (1:100, clone 29E.2A3, mouse IgG2b, κ, Biolegend, #329707) or isotype control (1:100, clone MPC-11, mouse mouse IgG2b, κ, Biolegend, #400319.

Techniques: Binding Assay, Negative Control, Positive Control, Functional Assay, Enzyme-linked Immunosorbent Assay, Blocking Assay, Incubation

(A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype IgG and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.

Journal: Cancer cell

Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

doi: 10.1016/j.ccell.2018.05.009

Figure Lengend Snippet: (A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype IgG and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.

Article Snippet: Mouse IgG2b isotype control (clone MPC-11) , BioXcell , Cat# BE0086.

Techniques: Incubation, Comparison, Derivative Assay, Control, Cell Culture, Luminex

(A–B) Heatmaps with unsupervised hierarchical clustering and single-sample gene set enrichment analysis (ssGSEA) scores of TFH-associated genes in gene expression data sets from functionally validated mouse splenic (A) and donor-derived (B) 4PD1hi, 4PD1− and Tregs. *, Wilcoxon matched-pairs signed-rank test p=0.03125 (mean ± SEM; A, n=3; B, n=5). (C) 4PD1hi (percent of CD4+ T cells, left; proportion of total cells, right) in tumors from B16-bearing Batf KO or wild-type (WT) mice treated with αCTLA-4 or control isotype IgG (100 μg x4) as assessed by FACS (mean ± SEM; WT mice, n=10; Batf KO mice, n=6–7; unpaired t test) or immunofluorescence staining (IF; mean ± SEM; n=3; unpaired t test). (D) CD86 MFI on circulating B220+CD45+ B cells from B16-bearing mice treated with αCTLA-4 or control isotype IgG (100 μg x4) (left; mean ± SEM; n=9–10, unpaired t test), and on circulating CD19+CD45+ B cells before and during ipilimumab treatment (ipi) in metastatic melanoma patients (right; 3 mg/kg, q3wks; n=16; paired t test). (E,F) In vitro suppression assays with 4PD1hi, memory CD4+ T cells (CD44hiPD-1−Foxp3−CD4+ T cells, Tmem) and Tregs from tumors (E) and spleens (F) of αCTLA-4-treated (100 μg x4) B16-bearing Foxp3-GFP mice at the indicated effector:target ratios. 4PD1hi, Tmem and Tregs FACS gating strategy and baseline CD44 expression after sorting is depicted (E top). Data show mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=3; E, unpaired t test; F, 2-way ANOVA, 4PD1hi and Tregs vs Tmem). ** = p<0.01, **** = p<0.0001. See also Figure S6.

Journal: Cancer cell

Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

doi: 10.1016/j.ccell.2018.05.009

Figure Lengend Snippet: (A–B) Heatmaps with unsupervised hierarchical clustering and single-sample gene set enrichment analysis (ssGSEA) scores of TFH-associated genes in gene expression data sets from functionally validated mouse splenic (A) and donor-derived (B) 4PD1hi, 4PD1− and Tregs. *, Wilcoxon matched-pairs signed-rank test p=0.03125 (mean ± SEM; A, n=3; B, n=5). (C) 4PD1hi (percent of CD4+ T cells, left; proportion of total cells, right) in tumors from B16-bearing Batf KO or wild-type (WT) mice treated with αCTLA-4 or control isotype IgG (100 μg x4) as assessed by FACS (mean ± SEM; WT mice, n=10; Batf KO mice, n=6–7; unpaired t test) or immunofluorescence staining (IF; mean ± SEM; n=3; unpaired t test). (D) CD86 MFI on circulating B220+CD45+ B cells from B16-bearing mice treated with αCTLA-4 or control isotype IgG (100 μg x4) (left; mean ± SEM; n=9–10, unpaired t test), and on circulating CD19+CD45+ B cells before and during ipilimumab treatment (ipi) in metastatic melanoma patients (right; 3 mg/kg, q3wks; n=16; paired t test). (E,F) In vitro suppression assays with 4PD1hi, memory CD4+ T cells (CD44hiPD-1−Foxp3−CD4+ T cells, Tmem) and Tregs from tumors (E) and spleens (F) of αCTLA-4-treated (100 μg x4) B16-bearing Foxp3-GFP mice at the indicated effector:target ratios. 4PD1hi, Tmem and Tregs FACS gating strategy and baseline CD44 expression after sorting is depicted (E top). Data show mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=3; E, unpaired t test; F, 2-way ANOVA, 4PD1hi and Tregs vs Tmem). ** = p<0.01, **** = p<0.0001. See also Figure S6.

Article Snippet: Mouse IgG2b isotype control (clone MPC-11) , BioXcell , Cat# BE0086.

Techniques: Gene Expression, Derivative Assay, Control, Immunofluorescence, Staining, In Vitro, Expressing, Activation Assay

(A) In vitro suppression assays with 4PD1hi, Tregs and 4PD1− from spleens of sRBC-immunized or control B16-bearing Foxp3-GFP mice at the indicated ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD4+ T cells, and Foxp3 and PD-1 MFI in CD45.1− 4PD1hi, 4PD1− or Tregs from the same co-cultures after 48-hr incubation (n=2–3; 2-way ANOVA, NT-4PD1hi vs sRBC-4PD1hi). (B) In vitro suppression assays with CXCR5+ and CXCR5− 4PD1hi, 4PD1− and Tregs from spleens (SP) and tumors (TM) of naive and B16-bearing (TB) Foxp3-GFP mice immunized with sRBC. Mean ± SD proliferation (CTVlow) of target CD45.1+CD4+ T cells and quantification of IL-2 by Luminex-based bead immunoassay in culture supernatants after 72-hr incubation with effector cells (1:1 ratio; 4×104 cells from SP; 1×104 cells from TM; n=2–4; unpaired t test). (C) In vitro suppression assays with 4PD1hi, CD44hiPD-1−Foxp3−CD4+ Tmem and Foxp3+ Tregs from spleens of sRBC-immunized Foxp3-GFP mice at the indicated effector:target ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=2–3; 2-way ANOVA, 4PD1hi and Tregs vs Tmem). (D) Average ± SEM tumor diameter of B16-bearing Sh2d1a (SAP) KO and WT C57BL/6J mice treated with αCTLA-4 or control isotype IgG (100 μg x4) starting on day 7 after tumor implantation (suboptimal treatment) (n=4–5; 2-way ANOVA with Bonferroni correction). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S7.

Journal: Cancer cell

Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

doi: 10.1016/j.ccell.2018.05.009

Figure Lengend Snippet: (A) In vitro suppression assays with 4PD1hi, Tregs and 4PD1− from spleens of sRBC-immunized or control B16-bearing Foxp3-GFP mice at the indicated ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD4+ T cells, and Foxp3 and PD-1 MFI in CD45.1− 4PD1hi, 4PD1− or Tregs from the same co-cultures after 48-hr incubation (n=2–3; 2-way ANOVA, NT-4PD1hi vs sRBC-4PD1hi). (B) In vitro suppression assays with CXCR5+ and CXCR5− 4PD1hi, 4PD1− and Tregs from spleens (SP) and tumors (TM) of naive and B16-bearing (TB) Foxp3-GFP mice immunized with sRBC. Mean ± SD proliferation (CTVlow) of target CD45.1+CD4+ T cells and quantification of IL-2 by Luminex-based bead immunoassay in culture supernatants after 72-hr incubation with effector cells (1:1 ratio; 4×104 cells from SP; 1×104 cells from TM; n=2–4; unpaired t test). (C) In vitro suppression assays with 4PD1hi, CD44hiPD-1−Foxp3−CD4+ Tmem and Foxp3+ Tregs from spleens of sRBC-immunized Foxp3-GFP mice at the indicated effector:target ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=2–3; 2-way ANOVA, 4PD1hi and Tregs vs Tmem). (D) Average ± SEM tumor diameter of B16-bearing Sh2d1a (SAP) KO and WT C57BL/6J mice treated with αCTLA-4 or control isotype IgG (100 μg x4) starting on day 7 after tumor implantation (suboptimal treatment) (n=4–5; 2-way ANOVA with Bonferroni correction). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S7.

Article Snippet: Mouse IgG2b isotype control (clone MPC-11) , BioXcell , Cat# BE0086.

Techniques: In Vitro, Control, Activation Assay, Incubation, Luminex, Tumor Implantation

KEY RESOURCES TABLE

Journal: Cancer cell

Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

doi: 10.1016/j.ccell.2018.05.009

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse IgG2b isotype control (clone MPC-11) , BioXcell , Cat# BE0086.

Techniques: Purification, Blocking Assay, Control, Virus, Recombinant, Staining, Gene Expression, Knock-Out, Transgenic Assay, Software